Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blueberries MedicalBBRRF +12.88% 3-Year EBITDA Growth Rate is 15.70% as of Mar. 2026, which is 16% below its 10-year median of 18.70. The stock has 2 warning signs investors should review. Among 808 Drug Manufacturers companies, Blueberries Medical ranks better than 61.01% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 42.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 31.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Blueberries Medical was 62.70% per year. The lowest was -20.90% per year. And the median was 18.70% per year.
Blueberries Medical (OTCPK:BBRRF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Blueberries Medical 3-Year EBITDA Growth Rate Related Terms
BBRRF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blueberries Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blueberries Medical 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blueberries Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Blueberries Medical's 3-Year EBITDA Growth Rate falls into.
Blueberries Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.70% mean?
Blueberries Medical (BBRRF) has a 3-Year EBITDA Growth Rate of 15.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Blueberries Medical and its competitors. This is 16% below median its historical median of 18.70. According to the industry distribution chart, Blueberries Medical ranks #315 out of 808 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Blueberries Medical's 3-Year EBITDA Growth Rate too high?
Blueberries Medical's current 3-Year EBITDA Growth Rate of 15.70% is 16% below median its 10-year median of 18.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Blueberries Medical's value of 15.70% is 76.4% above this industry median. Based on the distribution chart, Blueberries Medical ranks #315 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Blueberries Medical's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Blueberries Medical ranks #315 out of 808 companies for 3-Year EBITDA Growth Rate. This puts Blueberries Medical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Blueberries Medical's value of 15.70% is 76.4% above this benchmark. While the company's 10-year median is 18.70 vs. the industry median of 8.90, Blueberries Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blueberries Medical's current 3-Year EBITDA Growth Rate of 15.70% is 76.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Blueberries Medical and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blueberries Medical's current 3-Year EBITDA Growth Rate is 15.70%, which is 16% below median its own 10-year median of 18.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blueberries Medical stock overvalued right now?
Blueberries Medical (BBRRF) has a current 3-Year EBITDA Growth Rate of 15.70%. The current 3-Year EBITDA Growth Rate is 15.70%, which is 16% below median its 10-year median of 18.70 and 76.4% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Blueberries Medical (BBRRF), the current 3-Year EBITDA Growth Rate is 15.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Blueberries Medical Corp is a consumer science company focused on health, wellness and longevity. The company also distributes functional supplements, wellness products, and natural ingredients. It cultivates, produces, and distributes cannabidiol (CBD) and THC (tetrahydrocannabinol) based medical cannabis domestically as well as internationally. The company generates all of its revenues from Colombia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBRRF has been successfully added to your 
